Translating Pharmacomicrobiomics: From Microbiome Cloud Uncertainty to Pharmaceutical and Clinical Application(s)

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Head of the Microbiology and Immunology Research Program, Children's Cancer Hospital of Egypt; Professor, Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University
    BIOGRAPHY

Abstract

The Human Microbiome Project was conceived almost 15 years ago, as an extension of the Human Genome Project, to explore the diversity of human-associated microorganisms at multiple body sites (skin, mouth, nose, colon, and vagina) and their impact on human health.  Pioneering studies highlighted the extent of intra- and inter-individual microbiome variations, and how these variations played key roles in nutrition, health, disease, and immunity. Different models were proposed to describe the human microbiome, likening it, for example, to a missing organ or a second genome. The origin and definition of the term microbiome is discussed, and different views of illustrating or modeling the microbiome are debated, including a proposed cloud model. Subsequently, the major obstacles/bottlenecks related to microbiome analysis are listed, and examples of analysis strategies that address them are presented. Moreover, recent research results are presented on microbiome alterations in hepatitis C and conjunctivitis patients, as well as the interplay between the human and surrounding environmental microbes among nurses and drug factory workers. Finally, the nascent field of pharmacomicrobiomics, or drug–microbiome interactions, is introduced and discussed in the light of ‘the microbiome cloud model’. Key examples of drugs that are dramatically affected by gut and vaginal microbes are presented. Finally, recently developed web resources and big data analysis tools are demonstrated and applied to accelerate drug-microbiome interactions in the hope of customizing therapeutic intervention, minimizing drug toxicity, and improving the therapeutic outcomes of available medicines.


Learning Objectives:

1. List and compare the different definitions of, and images associated with, the terms microbiome and human microbiome.

2. Define pharmacomicrobiomics, and differentiate the term from the associated subfields of pharmacometagenomics, pharmacometabonomics, pharmacometabonomics

3. List the major bottleneck in the microbiome analysis pipeline, and mention at least one strategy to address each of them

4. List potential applications of pharmacomicrobiomics in precision medicine (therapeutics and diagnostics).


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
JAN 13, 2022 9:00 AM PST
C.E. CREDITS
JAN 13, 2022 9:00 AM PST
Date: January 13, 2022 Time: 09:00am (PST), 12:00pm (EST) Recently, the Infectious Disease Society of America released guidance on how to approach treatment of infections caused by multidrug...
Loading Comments...
Show Resources